2-(4-trifluoromethyl-phenoxy)-thiazole-4-carboxylic acid 3,5-difluoro-4-methanesulfonylamino-benzylamide | 1202643-23-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-trifluoromethyl-phenoxy)-thiazole-4-carboxylic acid 3,5-difluoro-4-methanesulfonylamino-benzylamide
• 英文别名: N-[[3,5-difluoro-4-(methanesulfonamido)phenyl]methyl]-2-[4-(trifluoromethyl)phenoxy]-1,3-thiazole-4-carboxamide
• CAS: 1202643-23-9
• 化学式: C₁₉H₁₄F₅N₃O₄S₂
• 分子量: 507.462
• InChiKey: BHSSEVRLKPCYRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  2-chloro-thiazole-4-carboxylic acid 3,5-difluoro-4-methanesulfonylamino-benzylamide 、 potassium carbonate 、 间三氟甲基苯酚 以to give the title compound (42 mg, 51%)的产率得到2-(4-trifluoromethyl-phenoxy)-thiazole-4-carboxylic acid 3,5-difluoro-4-methanesulfonylamino-benzylamide
  参考文献：
  名称：

  Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same

  摘要：

  本发明涉及一种新型化合物，其异构体或药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及包含该化合物的制药组合物。本发明提供了一种预防或治疗疾病的制药组合物，如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合征、排便紧迫、呼吸系统疾病、皮肤、眼部或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏病等。

  公开号：

  US08691855B2

文献信息

• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Woo Byoung Young

  公开号：US20110152318A1

  公开（公告）日：2011-06-23

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及一种新型化合物，其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及包含该化合物的制药组合物。本发明提供了一种用于预防或治疗疾病的制药组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合症、排便紧迫、呼吸系统疾病、皮肤、眼或黏膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏病等疾病。
• SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST
  申请人：Amorepacific Corporation

  公开号：EP2307394B1

  公开（公告）日：2012-09-26
• [EN] NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS, ISOMÈRE CORRESPONDANT OU SELS PHARMACEUTIQUEMENT ACCEPTABLES CORRESPONDANTS EN TANT QU'ANTAGONISTE DU RÉCEPTEUR VANILLOÏDE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：AMOREPACIFIC CORP

  公开号：WO2010002209A2

  公开（公告）日：2010-01-07

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.